

Please type a plus sign (+) inside this box →


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED


NOV 14 2002

TECH CENTER 1600 2900

Examiner Signature		Date Considered	1/29/03
-----------------------	---	--------------------	---------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.



RECEIVED

NOV 14 2002

TECH CENTER 1600/2900

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/601,490
				Filing Date	September 21, 2000
				First Named Inventor	Désiré José COLLEN
				Group Art Unit	1652
				Examiner Name	Delia M. Ramirez
Sheet	4	of	4	Attorney Docket Number	702-001463


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T ²
DR	BE	COLLEN, D. et al. "Isolation and Characterisation of Natural and Recombinant Staphylokinase" <i>Fibrinolysis</i> 6: 203-213 (1992)	
	BF	COLLEN, D. et al. "Comparative Thrombolytic and Immunogenic Properties of Staphylokinase and Streptokinase" <i>Fibrinolysis</i> 6: 232-242 (1992)	
	BG	BIAcore Methods Manual "Immobilization" pp: 5-2 through 5-4, Pharmacia Biosensor AB, Uppsala, Sweden	
	BH	Gibaldi, M. et al. "Pharmacokinetics" 2 nd Ed. Marcel Dekker Inc., New York, N.Y. pp: 45-111 (1983)	
	BI	INADA, Y. et al. "Biomedical and Biotechnological Applications of PEG- and PM-modified Proteins" <i>Tibtech</i> 13: 86-91 (1995)	
	BJ	RABIJNS, A. et al. "Three-dimensional Structure of Staphylokinase, a Plasminogen activator with Therapeutic Potential" <i>Nature Structural Biology</i> 4(5): 357-360 (1997)	
DR	BK	JESPERS, S. et al. "Structural and Functional Basis of Plasminogen Activation by Staphylokinase" <i>Thromb Haemost</i> 81: 479-485 (1999)	

Examiner Signature		Date Considered	1/29/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



NOV 14 2002

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/2001. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/601,490
				Filing Date	September 21, 2000
				First Named Inventor	Désiré José COLLEN
				Group Art Unit	1652
				Examiner Name	Delia M. Ramirez
Sheet	2	of	4	Attorney Docket Number	702-001463

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T ²
	AC	LACK, C.H. "Staphylokinase: an Activator of Plasma Protease" <i>Nature</i> 161: 559-560 (1948)	
	AD	LEWIS, J.H. et al. "A Proteolytic Enzyme System of the Blood. III. Activation of Dog Serum Profibrinolysin by Staphylokinase" <i>Am J Physiol</i> 166: 594-602 (1951)	
	AE	VANDERSCHUEREN, S. et al. "A Randomized Trial of Recombinant Staphylokinase Versus Alteplase for Coronary Artery Patency in Acute Myocardial Infarction" <i>Circulation</i> 92(8): 2044-2049 (1995)	
	AF	SAKO, T. et al. "Cloning and Expression of the Staphylokinase Gene of <i>Staphylococcus aureus</i> in <i>Escherichia coli</i> " <i>Mol Gen Genet</i> 190: 271-277 (1983)	
	AG	BEHNKE, D. et al. "Cloning and expression in <i>Escherichia coli</i> , <i>Bacillus subtilis</i> , and <i>Streptococcus sanguis</i> of a gene for staphylokinase – a bacterial plasminogen activator" <i>Mol Gen Genet</i> 210: 528-534 (1987)	
	AH	SAKO, T. et al. "Nucleotide sequence of the staphylokinase gene from <i>Staphylococcus aureus</i> " <i>Nucleic Acids Research</i> 11(22): 7679-7683 (1983)	
	AI	SAKAI, M. et al. "Mechanism of Fibrin-Specific Fibrinolysis by Staphylokinase: Participation of α_2 -Plasmin Inhibitor" <i>Biochem Biophys Res Comm</i> 162(2): 830-837 (1989)	
	AJ	MATSUO, O. et al. "Thrombolytic Properties of Staphylokinase" <i>Blood</i> 76(5): 925-929 (1990)	
	AK	LIJNEN, H.R. et al. "On the Mechanism of Fibrin-specific Plasminogen Activation by Staphylokinase" <i>J Biol Chem</i> 266(18): 11826-11832 (1991)	
	AL	LIJNEN, H.R. et al. "On the molecular interactions between plasminogen-staphylokinase, α_2 -antiplasmin and fibrin" <i>Biochim Biophys Acta</i> 1118: 144-148 (1992)	
	AM	SILENCE, K. et al. "Interaction between Staphylokinase, Plasmin(ogen), and α_2 -Antiplasmin" <i>J Biol Chem</i> 268(13): 9811-9816 (1993)	
	AN	SILENCE, K. et al. "Regulation by α_2 -Antiplasmin and Fibrin of the Activation of Plasminogen with Recombinant Staphylokinase in Plasma" <i>Blood</i> 82(4): 1175-1183 (1993)	
	AO	SAKHAROV, D.V. et al. "Interactions between Staphylokinase, Plasmin(ogen), and Fibrin" <i>J Bio Chem</i> 271(44): 27912-27918 (1996)	
	AP	SCHLOTT, B. et al. "Staphylokinase Requires NH ₂ -terminal Proteolysis for Plasminogen Activation" <i>J Bio Chem</i> 272(9): 6067-6072 (1997)	

Examiner Signature		Date Considered	1/29/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

{W0016809.1}

Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/2001. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of


4

Complete if Known

Application Number	09/601,490
Filing Date	September 21, 2000
First Named Inventor	Désiré José COLLEN
Group Art Unit	1652
Examiner Name	Delia M. Ramirez
Attorney Docket Number	702-001463

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.
DR	AQ	COLLEN, D. et al. "Comparative Immunogenicity and Thrombolytic Properties Toward Arterial and Venous Thrombi of Streptokinase and Recombinant Staphylokinase in Baboons" <i>Circulation</i> 87(3): 996-1006 (1993)
↑	AR	WHITE, H. "Thrombolytic treatment for recurrent myocardial infarction" <i>Br Med J</i> 302: 429-430 (1991)
	AS	GASE, A. et al. "Functional Significance of NH ₂ - and COOH-Terminal Regions of Staphylokinase in Plasminogen Activation" <i>Thromb Haemost</i> 76(5): 755-760 (1996)
	AT	SCHLOTT, B. et al. "High Yield Production and Purification of Recombinant Staphylokinase for Thrombolytic Therapy" <i>Bio/Technology</i> 12: 185-189 (1994)
	AU	HORTON, R.M. et al. "Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension" <i>Gene</i> 77: 61-68 (1989)
	AV	KARLSSON, R. et al. "Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system" <i>J Immunol Methods</i> 145: 229-240 (1991)
	AW	BRADFORD, M.M. "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding" <i>Anal Biochem</i> 72: 248-254 (1976)
	AX	DEUTSCH, D.G. et al. "Plasminogen: Purification from Human Plasma by Affinity Chromatography" <i>Science</i> 170: 1095-1096 (1970)
	AY	VANDERSCHUEREN, S. et al. "Thrombolytic Therapy of Peripheral Arterial Occlusion with Recombinant Staphylokinase" <i>Circulation</i> 92(8): 2050-2057 (1995)
	AZ	COLLEN, D. et al. "Thrombolytic Properties of Poorly Immunogenic Variants of Recombinant Staphylokinase" <i>Fibrinolysis & Proteolysis</i> 12(Suppl. 1): 30 (1998)
	BA	COLLEN, D. et al. "Recombinant Staphylokinase Variants with Altered Immunoreactivity. III: Species Variability of Antibody Binding Patterns" <i>Circulation</i> 95(2): 455-562 (1997)
	BB	COLLEN, D. et al. "Recombinant Staphylokinase Variants with Altered Immunoreactivity. IV: Identification of Variants with Reduced Antibody Induction but Intact Potency" <i>Circulation</i> 95(2): 463-472 (1997)
	BC	COLLEN, D. et al. "Recombinant Staphylokinase Variants with Altered Immunoreactivity I: Construction and Characterization" <i>Circulation</i> 94(2): 197-206 (1996)
DR	BD	COLLEN, D. et al. "Recombinant Staphylokinase Variants with Altered Immunoreactivity. II: Thrombotic Properties and Antibody Induction" <i>Circulation</i> 94(2): 207-216 (1996)

Examiner Signature		Date Considered	1/29/03
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

{W0016809.1}

Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/2001. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.